Chongsoo Lee

Managing Director at Eutilex Co., Ltd.

Presenter

Eutilex Co., Ltd. is a South Korean biotech company specializing in the development of innovative cancer immunotherapies, with a focus on T-cell therapies. Founded in 2015, Eutilex aims to harness the immune system to eliminate cancer through T-cell-based technologies and immune checkpoint inhibitors. Core Technologies Eutilex's core technology involves engineering T-cells to more effectively recognize and attack cancer cells. Their T-cell and CAR-T cell therapies offer a powerful and precise treatment option by enabling T-cells to bind to and activate against antigens present on cancer cells. Additionally, Eutilex is developing immune checkpoint inhibitors and immune activators to "release the brakes" on the immune system, allowing for a more effective attack on cancer cells. Key Pipeline EU307 [Phase 1 in Korea]: A fourth-generation CAR-T therapy targeting GPC3, which is highly expressed in liver cancer, and co-expressing the immune-activating cytokine IL18. EU103 [Phase 1 in Korea]: An antibody therapy that blocks the function of M2 macrophages while converting them to M1 macrophages, thereby enhancing the body's immune response against cancer. EU101 [Phase 1/2 in Korea/US, Phase 1 in China]: An antibody therapy targeting the well-known T-cell co-stimulatory receptor 4-1BB, enhancing T-cell cytotoxicity, immune memory, and survival capabilities. EU204 [Phase 1/2a in Korea]: An EBV-positive T-cell therapy targeting NK/T-cell lymphoma, utilizing 4-1BB-based cancer antigen-specific T-cell isolation technology. In addition to these, Eutilex possesses core technologies and research capabilities for the prevention and treatment of zoonotic diseases. Beyond drug development, the company also engages in biosolution businesses, including non-clinical contract research organization (CRO) services and operations through GMP facilities.